Question 1

Is there any technical argument why Biopixlar is better than their competitors?

Jonas Hannestad · Accepted Answer

There are many interesting alternative technologies on the Bioprinting market. However, none of them are capable of printing high-resolution tissues in the same manner and with the same precision as it can be achieved with Biopixlar technology.

The leading competitive technologies within the bioprinting space utilise a bioink to suspend and support the cells, to allow for printing in air onto a surface (cells being embedded in the bioink). The bioprinting control is therefore tailored to position the bioink, not the cells. Thus, the cell positioning cannot be readily controlled by the bioprinter, as their location is determined by the encapsulation within the bioink.

The Biopixlar® platform offers the benefit of building tissues in standard cell culture media, a stark contrast to the gel/polymer matrix which is employed in other 3D bioprinting technologies. This results in very high cell viability typically exceeding 95%, when compared to standard cell culture. Features such as tissue organization and cell pattern density can be readily controlled.

Moreover, Biopixlar® holds a technological advantage by requiring a small sample size (cell number) for generating relevant tissues. Tissues can be generated from as low as about 100 cells to reach a satisfactory level of confluency. This becomes an extremely important feature when tissues are to be built directly from human primary, stem cells, or patient biopsies which are very scarce and valuable.

Question 2

Is there any technical argument why Biopixlar is better than their competitors?

Jonas Hannestad · Accepted Answer

There are many interesting alternative technologies on the Bioprinting market. However, none of them are capable of printing high-resolution tissues in the same manner and with the same precision as it can be achieved with Biopixlar technology.

The leading competitive technologies within the bioprinting space utilise a bioink to suspend and support the cells, to allow for printing in air onto a surface (cells being embedded in the bioink). The bioprinting control is therefore tailored to position the bioink, not the cells. Thus, the cell positioning cannot be readily controlled by the bioprinter, as their location is determined by the encapsulation within the bioink.

The Biopixlar® platform offers the benefit of building tissues in standard cell culture media, a stark contrast to the gel/polymer matrix which is employed in other 3D bioprinting technologies. This results in very high cell viability typically exceeding 95%, when compared to standard cell culture. Features such as tissue organization and cell pattern density can be readily controlled.

Moreover, Biopixlar® holds a technological advantage by requiring a small sample size (cell number) for generating relevant tissues. Tissues can be generated from as low as about 100 cells to reach a satisfactory level of confluency. This becomes an extremely important feature when tissues are to be built directly from human primary, stem cells, or patient biopsies which are very scarce and valuable.